Navigation Links
George Butler Joins Bionovo's Board of Directors
Date:3/13/2008

EMERYVILLE, Calif., March 13 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of George Butler, Ph.D., to the company's Board of Directors. Dr. Butler has extensive regulatory experience with pharmaceutical and biotech companies, and in particular in advancing cancer drug development and women's health.

"We are very excited to have George on board as we move into a new phase of the regulatory process with our advancing clinical trial programs," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. He added, "George led the development of hormonal drugs for breast cancer as prior head of global regulatory affairs at Astra Zeneca, making him a perfect fit with our platform at Bionovo in women's health and cancer."

Dr. Butler says, "I believe the exciting pipeline of Bionovo will attract the interest of large Pharma in deals for the individual compounds or perhaps a larger deal for the entire oncology pipeline. What is truly special about Bionovo is their excellent batting average for bringing drugs through pre-clinical to clinical phase, which is almost unheard of in the industry."

Dr. Butler has 30 years of experience primarily in drug development and regulatory affairs in large pharmaceutical companies in the US and Europe. He has been one of the leaders driving improvement in the development and regulatory environment, and in speeding up the regulatory process at both the FDA and EMEA. His professional experience includes leadership roles at AstraZeneca and Novartis, where he headed the global Regulatory Affairs group. He has a long track record across several therapeutic areas of successful regulatory approvals. He has also played a leading role in discussions between the pharmaceutical industry and managed care and other healthcare 'payers.' He now serves on a variety of regulatory advisory groups, as well as several private company boards of directors.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI." For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
2. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
3. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
4. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
5. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
6. Royea Joins Eklin Medical Systems as VP of Worldwide Sales
7. Eric K. Rowinsky Joins ADVENTRX Board of Directors
8. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
9. Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life
10. Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG
11. Mark Ostrowski Joins GenVault as Vice President of Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):